WO1999040946A3 - Methods and compositions for modulating leptin activity - Google Patents

Methods and compositions for modulating leptin activity Download PDF

Info

Publication number
WO1999040946A3
WO1999040946A3 PCT/US1999/002865 US9902865W WO9940946A3 WO 1999040946 A3 WO1999040946 A3 WO 1999040946A3 US 9902865 W US9902865 W US 9902865W WO 9940946 A3 WO9940946 A3 WO 9940946A3
Authority
WO
WIPO (PCT)
Prior art keywords
socs
leptin
hypothalamus
cis
action
Prior art date
Application number
PCT/US1999/002865
Other languages
French (fr)
Other versions
WO1999040946A2 (en
Inventor
Jeffrey S Flier
Christian Bjorbaek
Original Assignee
Beth Israel Hospital
Jeffrey S Flier
Christian Bjorbaek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Jeffrey S Flier, Christian Bjorbaek filed Critical Beth Israel Hospital
Priority to CA002320226A priority Critical patent/CA2320226A1/en
Priority to EP99906877A priority patent/EP1053007A2/en
Priority to AU26686/99A priority patent/AU2668699A/en
Priority to JP2000531197A priority patent/JP2002506004A/en
Publication of WO1999040946A2 publication Critical patent/WO1999040946A2/en
Publication of WO1999040946A3 publication Critical patent/WO1999040946A3/en
Priority to US10/430,683 priority patent/US20040087530A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Administration of leptin affects food intake and body weight in animals and humans by a mechanism involving actions on specific regions of the hypothalamus. CIS-1, SOCS-1, SOCS-2 and SOCS-3 genes were investigated for their ability to antagonize leptin action. In mammalian cell lines, SOCS-3 completely blocked leptin induced signal-transduction, whereas CIS, SOCS-1 and SOC-2 were without effect. SOCS-3 is a major target of leptin action in leptin responsive cells in the hypothalamus, and SOCS-3 is a potent inhibitor of leptin signaling. Increased SOCS-3 activity in leptin-responsive neurons is a potential mechanism for the leptin resistance observed in syndromes of obesity, affective mood disorders and reproductive disorders.
PCT/US1999/002865 1998-02-11 1999-02-10 Methods and compositions for modulating leptin activity WO1999040946A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002320226A CA2320226A1 (en) 1998-02-11 1999-02-10 Methods and compositions for modulating leptin activity
EP99906877A EP1053007A2 (en) 1998-02-11 1999-02-10 Methods and compositions for modulating leptin activity
AU26686/99A AU2668699A (en) 1998-02-11 1999-02-10 Methods and compositions for modulating leptin activity
JP2000531197A JP2002506004A (en) 1998-02-11 1999-02-10 Methods and compositions for modulating leptin activity
US10/430,683 US20040087530A1 (en) 1998-02-11 2003-05-06 Methods and compositions for modulating leptin activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7432098P 1998-02-11 1998-02-11
US4427898A 1998-03-19 1998-03-19
US09/044,278 1998-03-19
US60/074,320 1998-03-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US4427898A Continuation-In-Part 1998-02-11 1998-03-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US63724700A Continuation 1998-02-11 2000-08-11

Publications (2)

Publication Number Publication Date
WO1999040946A2 WO1999040946A2 (en) 1999-08-19
WO1999040946A3 true WO1999040946A3 (en) 1999-10-28

Family

ID=26721350

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/002865 WO1999040946A2 (en) 1998-02-11 1999-02-10 Methods and compositions for modulating leptin activity

Country Status (5)

Country Link
EP (1) EP1053007A2 (en)
JP (1) JP2002506004A (en)
AU (1) AU2668699A (en)
CA (1) CA2320226A1 (en)
WO (1) WO1999040946A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2335107C (en) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US7078174B1 (en) 1998-12-21 2006-07-18 The Walter & Eliza Hall Institute Of Medical Research Screening methods using SOCS box-containing peptides
WO2000063357A2 (en) * 1999-04-20 2000-10-26 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
SE9903953D0 (en) * 1999-11-01 1999-11-01 Sahltech Ab New use of the jak-stat system
AU2001240346B2 (en) * 2000-03-09 2006-09-14 The Walter And Eliza Hall Institute Of Medical Research Methods of regulating cytokine signalling
AUPQ614700A0 (en) 2000-03-09 2000-03-30 Walter And Eliza Hall Institute Of Medical Research, The A method and agents useful for same
AU8178401A (en) 2000-05-22 2001-12-03 Vlaams Interuniv Inst Biotech Receptor-based interaction trap
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
AU2067202A (en) * 2000-11-14 2002-05-27 Vlaams Interuniv Inst Biotech Functional fragment of the lectine receptor
AU2002950745A0 (en) * 2002-08-13 2002-09-12 The Walter And Eliza Hall Institute Of Medical Research A method and agents useful for same
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038586A1 (en) * 1995-05-30 1996-12-05 Smithkline Beecham Plc Method for the detection of compounds that modulate the effects of the obese protein
WO1997044347A1 (en) * 1996-05-21 1997-11-27 Smithkline Beecham Corporation Human cis protein
WO1998020023A1 (en) * 1996-11-01 1998-05-14 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines
WO1999023220A1 (en) * 1997-11-03 1999-05-14 Incyte Pharmaceuticals, Inc. Suppressor of cytokine signaling

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038586A1 (en) * 1995-05-30 1996-12-05 Smithkline Beecham Plc Method for the detection of compounds that modulate the effects of the obese protein
WO1997044347A1 (en) * 1996-05-21 1997-11-27 Smithkline Beecham Corporation Human cis protein
WO1998020023A1 (en) * 1996-11-01 1998-05-14 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines
WO1999023220A1 (en) * 1997-11-03 1999-05-14 Incyte Pharmaceuticals, Inc. Suppressor of cytokine signaling

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BJORBAEK C ET AL: "Divergent signaling capacities of the long and short isoforms of the leptin receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 51, 19 December 1997 (1997-12-19), pages 32686 - 32695, XP002113582 *
C BJRBAEK ET AL: "IDENTIFICATION OF SOCS-3 AS A POTENTIAL MEDIATOR OF CENTRAL LEPTIN RESISTANCE", MOLECULAR CELL, vol. 1, no. 1, March 1998 (1998-03-01), pages 619 - 625 625, XP002099320, ISSN: 1097-2765 *
MASAAKI MASUHARA ET AL: "Cloning and characterization of novel CIS family genes", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 239, no. 2, 20 October 1997 (1997-10-20), pages 439 - 446, XP002095405, ISSN: 0006-291X *

Also Published As

Publication number Publication date
AU2668699A (en) 1999-08-30
CA2320226A1 (en) 1999-08-19
WO1999040946A2 (en) 1999-08-19
JP2002506004A (en) 2002-02-26
EP1053007A2 (en) 2000-11-22

Similar Documents

Publication Publication Date Title
WO1999040946A3 (en) Methods and compositions for modulating leptin activity
TOGAWA et al. Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance
M Brudzynski Pharmacology of ultrasonic vocalizations in adult rats: significance, call classification and neural substrate
Zhu et al. Calcium and 1α, 25‐dihydroxyvitamin D3 target the TNF‐α pathway to suppress experimental inflammatory bowel disease
Peña et al. Effects of maternal care on the development of midbrain dopamine pathways and reward‐directed behavior in female offspring
Gupta et al. Protective effect of trans-resveratrol against kainic acid-induced seizures and oxidative stress in rats
Ey et al. Absence of deficits in social behaviors and ultrasonic vocalizations in later generations of mice lacking neuroligin4
Atalayer et al. Food demand and meal size in mice with single or combined disruption of melanocortin type 3 and 4 receptors
Gluckman et al. How evolutionary principles improve the understanding of human health and disease
Kapahi et al. Positive correlation between mammalian life span and cellular resistance to stress
Mandell et al. Psychochemical Research Studies in Man: Research approaches to the chemistry of the mind of man, although promising, are difficult to interpret.
Easton et al. The circadian Clock mutation increases exploratory activity and escape‐seeking behavior
Aloisi et al. Sex-dependent effects of formalin and restraint on c-Fos expression in the septum and hippocampus of the rat
Kubo et al. Calorie source, calorie restriction, immunity and aging of (NZB/NZW) F1 mice
Kinney-Forshee et al. Could a deficiency in growth hormone signaling be beneficial to the aging brain?
Merritt et al. Mouse genetic differences in voluntary wheel running, adult hippocampal neurogenesis and learning on the multi-strain-adapted plus water maze
Pesanti et al. Colchicine effects on lysosomal enzyme induction and intracellular degradation in the cultivated macrophage.
Miyakawa et al. Radial maze performance, open-field and elevated plus-maze behaviors in Fyn-kinase deficient mice: further evidence for increased fearfulness
Ahern et al. Brain regional differences in social encounter-induced Fos expression in male and female rats after post-weaning social isolation
Ushakova et al. Modification of gene expression by dietary antioxidants in radiation-induced apoptosis of mice splenocytes
Reshetnikov et al. Impact of mothers’ experience and early‐life stress on aggression and cognition in adult male mice
Sillar et al. From tadpole to adult frog locomotion
Haleem Attenuation of 8-OH-DPAT-induced decreases in 5-HT synthesis in brain regions of rats adapted to a repeated stress schedule
LaGraize et al. Behavioral evidence for competing motivational drives of nociception and hunger
Trosko et al. The role of modulated gap junctional intercellular communication in epigenetic toxicology

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2320226

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2000 531197

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999906877

Country of ref document: EP

Ref document number: 09637247

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999906877

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999906877

Country of ref document: EP